Cognixion and Blackrock Neurotech have entered a collaboration to enhance access to non-invasive brain-computer interface (BCI) research tools.
Blackrock Neurotech will distribute Cognixion’s Axon-R wearable BCI platform, facilitating integration with immersive computing applications.
The initiative aims to advance neurotechnology by providing research institutions with advanced tools for investigational and educational purposes.
The Axon-R platform is a non-invasive, wearable device designed for precise measurement and modulation of brain activity using visual stimuli, biofeedback, and neurofeedback.
The device, developed by Cognixion, is intended for investigational and educational use.
Blackrock Neurotech will serve as a non-exclusive distributor, offering the Axon-R to research institutions through its distribution network.
Blackrock Neurotech CEO Marcus Gerhardt said: “At Blackrock Neurotech, our mission is restoring capability.
“By expanding access to research-grade tools like Axon-R, we aim to support the early exploration of neural interfaces while maintaining our clinical focus on sovereign, high-fidelity implantable technologies that restore speech, movement, and sensation.”
Blackrock Neurotech, known for its implantable BCI solutions, will continue its focus on restoring speech, movement, and sensation.
However, the addition of the Axon-R system enables universities, hospitals, and academic programmes to engage more deeply in BCI research and education.
The collaboration allows for the collection of high-quality data from surface-level EEG alongside implanted BCI data in a time-synchronised manner.
The Axon-R device is not cleared by the US Food and Drug Administration (FDA), and supports investigational use in neuroscience, neurorehabilitation, and education.
Blackrock Neurotech acts solely as a distributor for research use and does not develop or clinically endorse the device.
Future investigations involving multi-modal research across non-invasive and implantable systems remain exploratory and subject to independent validation.
Cognixion CEO Andreas Forsland said: “This collaboration represents a powerful alignment of complementary technologies that will have an outsized impact across neurotechnology applications.
“Blackrock Neurotech’s implant technology combined with Cognixion’s AI and augmented reality platform will open new doors for researchers and clinicians alike, while providing transformative solutions to the individuals we ultimately serve.”
